Postmastectomy Pain Syndrome

Solmaz Fakhari1, Simin Atashkhoei2, Hojjat Pourfathi3, Haleh Farzin4, Eissa Bilehjani5

Abstract
Breast cancer, recognized as the common cancer among women, is one of the important causes of morbidity and mortality worldwide. With regard to developments presented in screening, diagnosis, and especially therapies of this disease, survival of patients has improved in recent years, and as a result, the population at risk of complications attributable to treatment has increased, as well. Postmastectomy pain is one of the life-threatening complications of breast cancer. The nature of the mentioned pain is commonly neuropathic with abnormal sensation in intercostal nerve distribution region of upper and lateral parts of thorax, axilla, and medial and posterior parts of arm and shoulder. This pain strongly affects patients’ quality of life. At present, the strongest theory about the etiology and mechanism of this phenomenon is related to the neuralgia of intercostobrachial nerve caused by the damage to the nerves after mastectomy. The type of surgery, especially complete axillary dissection (CAD), radiotherapy, chemotherapy, age, pre- and post-operative breast pain, type and size of tumor, all are considered as important risk factors. The best method for prevention and treatment of postmastectomy pain syndrome (PMPS) is multimodal approach. As the best treatment is prevention, may be prevention of this syndrome with consideration of the causative factors, timely resolution of these factors and improvement of surgery techniques could be achieved. Treatment approaches include both pharmacological interventions and non-pharmacological strategies. Pharmacotherapy is the major treatment of cancer-related pains. Intercostal nerve block, radiofrequency pulse, stellate ganglion block, neuromodulation techniques, intrathecal drug delivery, epidural injections of local anesthetic, mastectomy, and use of botulinum, complementary and alternative therapies, scrambler therapy, acupuncture, yoga, and music therapy are the novel proposed strategies in this regard. Employing proper treatments can improve patients’ quality of life.

Keywords: Postmastectomy pain, Breast cancer, Neuropathic Pain, Intercostobrachial nerve

Introduction
Breast cancer is a common cancer-affecting women. It is an important cause of female morbidity and mortality worldwide and accounts for more than 30% of all new cases of cancer in females (1). Prevalence of this cancer is varying in different countries, which results from many factors such as age, race, socioeconomic status, lifestyle, reproductive history, family history, etc (2,3).

With the exception of Japan, breast cancer has higher incidence rate in developed countries in comparison with developing countries. The National Cancer Institution-Cairo estimates that 12.7% of women are exposed to breast cancer diagnosis over their lifetime. Currently, 80% of patients have presented a 5-year survival due to early diagnosis and improvements of management in this regard (1,4-6). Developments in screening, diagnosis, and especially innovative therapies have positive effects on reducing mortality rate, which ultimately help patients frequently survive several years. For instance, age-standardized mortality rate in 1977 equated to 30.6 deaths per 100,000 population, whereas it reached to 24.6 deaths per 100,000 population in 2002 (2, 7-10). Considering decreased breast cancer-related mortality rate, the population at risk of complications attributable to treatment of this disease, especially after mastectomy, has increased (7,9). As treatment of breast cancer usually starts with surgery, approximately 60% of patients undergo surgery for primary tumor resection, axillary node staging, or mastectomy (8,10).

The side effects associated with breast cancer treatment can occur in about 90% of patients. These complications may continue for months or years after treatment, having many implications on survivors’ quality of life (5). One of the life-threatening complications is occurrence of chronic pain following surgical treatment, which is known as postmastectomy pain syndrome (PMPS) (11). The present study aimed at reviewing symptoms, risk factors, etiology, prevalence rate, prevention, and treatment methods in this regard.

Epidemiology
PMPS is a distinctive syndrome with chronic and debilitating neuropathic pain, which can develop after cancer surgery including radical mastectomy, modified radical
mastectomy, and segmental mastectomy (lumpectomy) associated with axillary lymph node dissection (3,12,13). It is estimated that almost 25%-60% of patients suffer from chronic pain after breast cancer-related surgery (11). Wood first reported this pain in late 1970, and then Folly et al described PMPS consisting of pain and sensory disorders following mastectomy (8).

**Etiology and Mechanism**

**Pathophysiologic Mechanism**

Exact etiology and mechanism involved in PMPS are indeterminate although it seems to be probably multifactorial (3,14). The nature of pain is commonly chronic neuropathic, which results from nociceptive axonal injury (3,10).

It is believed that common cause may be neural pathway damage, particularly damage of intercostobrachial nerve, which is the cutaneous lateral branch of T2, during the surgery performed on breast and axillary area. Cutaneous lateral T2 branch (intercostobrachial) supplies supper part of thorax, upper and internal portion of arm and passes through axilla (3,15). Axillary dissection is associated with intercostobrachial nerve damage due to stretching during retraction or frank transection (10). One study indicated that in spite of maintaining brachial plexus and peripheral nerves, the damage caused by compression or pressure could result in PMPS. Another study reported that 80%–100% of patients undergoing mastectomy and axillary dissection are affected by intercostobrachial nerve damage (16).

Symptoms can usually occur in nerve distribution area; however, the most common theory for PMPS onset is sensory type of damage to intercostobrachial nerve (3,15). One neurologic study performed on patients with PMPS demonstrated that intercostobrachial nerve damage can occur in almost all patients (16). It is obvious that the type of breast surgery influences the prevalence of PMPS. It appears that prevalence of PMPS following breast conservation treatment is higher than its prevalence following modified radical mastectomy. Lower prevalence has been observed after sentinel node biopsy, which can be explained by invasive nature of complete axillary dissection (CAD) in comparison with sentinel node biopsies (SLND), recognized as the latest technique removing only cancer draining lymph node. In other words, there is good chance for preservation of nerve and vasculature in this situation (15-18). Post-simple mastectomy and laminectomy PMPS can usually occur due to injury to internal branch of intercostobrachial.

**Risk Factors**

It has been acknowledged that radiotherapy aggravates surgery-induced injury (15). Gerber et al in their study indicated higher prevalence of PMPS after one to even six years following lumpectomy associated with radiotherapy (19). However, radiotherapy can result in further damages to intercostobrachial and lead to exacerbation of PMPS. In addition, chemotherapy drugs, e.g. taxol, vincristine, and platinum, and lymph edema affect pain severity and discomfort caused by operation (15,20). In patients suffering from chronic neuropathic pain, alteration in CNS pain-modulatory mechanism and remodeling of cerebral portions that account for processing of painful stimulations can be considered as the possible reasons. In these patients, limbic system is hypersensitized to painful stimulations and leads to development of feedback between damaged sensory nerves and excitation pain center in brain (15,21).

Various studies have considered the association between adjuvant cancer therapy and PMPS. Carpenter et al. reported high prevalence of PMPS among women undergoing lumpectomy and chemo-radiotherapy (22).

Other risk factors include prior history of headache, being younger than 50 years old (especially 35 years old), genetic sensibility, psychosocial situation, marital status, employment status, housing, presence of post-operative pain, smoking, and presence of pain during peri-operative period (23-25). It seems that tumor in younger patients is negative estrogen-response and high grade. Furthermore, the type of tumor is proliferative and frequently induces vascular invasion (10,11). In one study, symptoms of PMPS were shown in 65% of patients within the age range of 30–45, whereas the rate was 26% in women aged 70 and over (15).

The larger size of tumor, post-operative complications (e.g. infection and bleeding), pre-operative depression, anxiety, and psychological stress play probably important roles in development of this syndrome (10,11,26). One study reported that PMPS is more common in patients with previous history of breast surgery and in patients with their tumor located in the upper lateral quarter (27). El-Sayed anf Ali found an association between educational level and dimensions of quality of life score. Patients with lower educational level had better physical and psychological status (1). Other studies stated that over use of arm (62%), straining (42%), sudden movements (38%), cold (16%), stress and edema (14%), cough (13%), immobility, arm compression, and prolonged standing (11%) can exacerbate symptoms of PMPS. Overall, incidence of PMPS varies between 20%-50% in the conducted studies (9,18,22).

**Symptoms**

PMPS is a chronic neuropathic pain that typically occurs as a continuous pain in association with abnormal sensation in inter-costal nerve distribution region of upper and lateral parts of thorax, axilla, and medial and posterior parts of arm and shoulder. Symptoms are shock-like with tingling pain sensation and burning pain related to chronic dysesthesia or shooting pain, pressure sensation, numbness, or pricking (10,12,18,22). Pain on ipsilateral site of surgery can occur in anterior part of chest, axilla, and mid and upper parts of arm and shoulder. Pain may be present at least 4 days per week or may last for longer than 3 months. According to IASP definition, pain sustains over normal adequate duration to allow healing. Based on nu-
merical rating scale (NRS), it has an average intensity of at least 3 on a scale from 0 to 10 (7,9,11,23,28). Chronic neuropathic pain related to PMPS with enough severity can interfere with sleep and daily activity performance, and poor treatment can result in immobilized patient or sever lymph edema, frozen shoulder syndrome, and complex regional pain (CRPS) (2).

Pain typically occurs immediately after post-operative period; however, it may initiate with a delay of 6 months and longer after surgery and last for years (11). According to Miguel et al, incidence of pain was reported as follow: axillary pain (84%), upper part of arm pain (74%), pin in upper part of chest pain (58%), and shoulder pain (32%) (12).

**Quality of Life**

PMPS neuropathic pain has major impacts on patients’ health, function, and quality of life. Chronic pain has interferences with physical and occupational functions, mood and sleep, and relationships and enjoyment of life. In 50% of patients, pain interferes with daily activity and may lead to sleep disturbances (11).

However, some interventions are required to improve patients’ symptoms, quality of life, and functional capacity (3).

**Prognosis**

This chronic pain syndrome has been frequently underestimated and poorly managed (12); however, in a number of studies, it was indicated that its intensity and associated sensory abnormalities diminished over time (10).

**Prevention**

**Improvement of Technique**

Although protection of intercostobrachial nerve is clinically difficult in practice, careful protection or dissection may decrease occurrence of sensory deficits and intercostobrachial neuralgia (ICN). SLND, which is preferred to CDA, is a better technique that can decrease sensory deficits and ICN. Hence, CDA is only performed in lymphatic node involvement cases (9,10).

**Alleviation of Risk Factors**

Severe acute pre-operative or post-operative pain is suggested as a contributing risk factor for some pain syndromes such as PMPS. It is recommended that acute pain should be appropriately managed to decrease post-operative chronic pain (10). Strazisar et al addressed the role of acute pain in post-operative chronic pain and showed positive impact of continuous infusion of local anesthetic by placing catheter on mastectomy surgery incision site (24). Moreover, Fassoulaki et al demonstrated that in patients undergoing mastectomy or lumpectomy in combination with axillary lymph node dissection, in which eutectic mixture of local anesthetic (EMLA) was used during pre-operative period for 3 days after surgery, chronic pain occurrence may be reduced 3 months after operation (29). Lakdja et al revealed beneficial effects of pre-operative administration of prophylactic Nonsteroidal anti-inflammatory drugs (NSAIDs) in PMPS, even 6 months after mastectomy (20).

However, based on inadequate evidence presented in this regard, objectives of prophylactic strategy must primarily include optimization of pain control during pre-operative period and decrease of nerve injury during surgery. In addition to EMLA, drugs such as gabapantine and mexiletine are found to be useful in patients undergoing breast surgery to reduce their post-operative acute and chronic pain (29,30). Reduction of surgery-related injury could be accompanied by improvement of operation methods and techniques effective in pain relief. In addition, improvement of screening methods for early diagnosis of breast cancer is another important factor in PMPS relief. Early detection is equivalent with smaller size of tumor, which in turn results in minimally invasive surgical treatment and facilitates utilization of breast cancer conservative techniques such as lumpectomy, breast-conserving surgery, extensive local excision, partial mastectomy, segmentectomy, or tylectomy (9,11,31). Even so, increased application of staging techniques with minimal invasion such as sentinel lymph node biopsy may decrease axillary dissection (32). In one study, paravertebral thoracic nerve block was used to reduce post-operative chronic and acute pains (33).

**Treatment**

According to the World Health Organization (WHO), pharmacotherapy is the major treatment of cancer-related pain. Based on the WHO analgesic ladder (Table 1), treatments proposed for cancer pain must follow sequential order, which is initiated by NSAIDs, and if analgesia is not sufficient, different types of opioids should be administered.

Adjunct drugs at any stages of WHO ladder can be added to the main drugs. Antidepressant agents such as gabapentinoids (e.g. gabapentin, pregabalin), antiepileptic drugs, narcoleptic drugs (e.g. chlorpromazine), serotonin reuptake inhibitors (e.g. fluoxetine, venlafaxine), NMDA antagonists (e.g. ketamine, memantine), lidocaine patch 5%, and short-term administration of steroids are used for treating chronic neuropathic pain (34).

The best method for prevention and treatment of PMPS is multimodal approach. The most appropriate treatment is prevention, which could be somewhat performed by application of and close attention to nerve preservation during surgery, using minimally invasive procedures and SLND rather than CAD.

Using EMLA 25 mg lidocaine and 25 mg prilocaine in 1 mL water in pre-operative period can decrease the need to post-operative analgesia and can reduce the possible occurrence of post-operative chronic neuropathic pain (15). Dini et al in their investigation showed the beneficial effects of capsaicin 0.025% in this regard (35). Capsaicin (Qutenza) 8% (concentrated extract of chili peppers) is an interesting and more potent drug in comparison with capsaicin 0.025% and is usually effective (sometimes works
Moderate Pain (or Mild Pain Unrelieved)

<table>
<thead>
<tr>
<th>Table 1. Three-Step Analgesic Ladder Based on the World Health Organization (WHO)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mild Pain</strong></td>
</tr>
<tr>
<td>Non-opioid analgesics:</td>
</tr>
<tr>
<td>Acetaminophen, ibuprofen, naproxen</td>
</tr>
<tr>
<td>+/- Adjuvants:</td>
</tr>
<tr>
<td>Anticonvulsants for neuropathic pain</td>
</tr>
<tr>
<td>And antidepressants or anxiolytics for coexisting mood disturbances</td>
</tr>
</tbody>
</table>

5. opioid is in fact limited data on causality and risk factors of PMPS. Treatment approaches include both pharmacological interventions and non-pharmacological strategies. However, current treatments of the PMPS are sub-optimal. Further investigations are required to achieve the appropriate developments in diagnosis and screening of breast cancer, and evaluation and treatment of PMPS that will provide less side effects, adequate analgesia, and finally, improved quality of life, and patient satisfaction in the future.

**Conclusion**

Frequency of PMPS due to advances in diagnosis and treatment of breast cancer is on the rise. Using proper treatments can improve the patients’ quality of life.

**Ethical Issues**

Not applicable.

**Conflict of Interests**

The authors have no conflicts of interest to disclose.

**Financial Support**

None.

**References**

43. Crew KD, Capodice JL, Greenlee H, et al. Randomized,


Copyright © 2017 The Author(s); This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.